NCT00920686 - Study of NXN 188 for the Treatment of Migraine With Aura | Biotech Hunter

Enrollment

239

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Migraine With Aura

Interventions

DRUG

NXN-188

NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules

DRUG

placebo

administered as 3 placebo hard gelatin capsules

DRUG

sumatriptan succinate

administered in a hard gelatin capsule with 2 capsules of placebo

Trial Locations (16)

10550

Elkind Headache Center, Mount Vernon

13760

Regional Clinical Research, Inc., Endwell

14609

Rochester Clinical Research, Inc, Rochester

27405

Headache Wellness Center, Greensboro

29464

Coastal Carolina Research Center, Inc, Mt. Pleasant

33702

Comprehensive Neuroscience, Inc., St. Petersburg

48104

Michigan Head-Pain and Neurological Institute, Ann Arbor

63141

Mercy Health Research, St Louis

65807

Headache Care Center/Clinvest, Springfield

66212

Vince and Associates Clinical Research, Overland Park

68134

Meridian Clinical Research, LLC, Omaha

84088

Advanced Clinical Research, Inc., West Jordan

90404

California Medical Clinic for Headache, Santa Monica

92056

The Research Center of Southern California, LLC, Oceanside

92660

C. Philip O'Carrroll, MD, Inc., Newport Beach

94109

San Francisco Headache Clinic, San Francisco